kringle-pharmaCo., Ltd.

NEWS

notice

  • All
  • Notice
  • AGM
Jun 14, 2021 Notice
It is an honor to announce that Dr. Kazuya Kitamura of Keio University School of Medicine / National Defense Medical College, Japan, was awarded the APSS CONGRESS Best Clinical Research Award at the 13th Combined Meeting of Asia Pacific Spine Society & Asia Pacific Paediatric Orthopaedic Society (APSS-APPOS 2021), which was held from June 9 to 12, 2021 at Kobe International Conference Center, Kobe City, Japan. Dr. Kitamura presented positive results from the Phase I/II clinical study in patients with acute spinal cord injury, entitled “Intrathecal administration of recombinant human hepatocyte growth factor for acute traumatic cervical spinal cord injury: double-blinded, placebo-controlled and randomized phase I/II study”.
Mar 08, 2021 Notice
Kringle Pharma today announces the addition of two clinical trial sites for Phase 3 of recombinant human HGF (KP-100IT) in acute spinal cord injury. The newly added sites are Japanese Red Cross Kobe Hospital as an acute care hospital and Aijinkai Rehabilitation Hospital as a convalescent rehabilitation hospital. New clinical sites expand opportunities for subject enrollment and confirming clinical feasibility of the KP-100IT therapy by a combination of the acute care and rehabilitation hospitals. Currently, five clinical sites including three national spinal cord injury centers are active for the ongoing Phase 3 trial in Japan. Detailed information about this Phase 3 trial is available at ClinicalTrials.gov using the identifier NCT04475224.
Dec 28, 2020 Notice
Kringle Pharma, a late clinical-stage biopharmaceutical company developing recombinant human hepatocyte growth factor for incurable diseases such as acute spinal cord injury and ALS, announces the closing of its initial public offering on the Tokyo Stock Exchange Mothers market.
Aug 31, 2020 Notice
Kringle Pharma and Maruishi Pharmaceutical enter into a capital and business partnership for KP-100IT in acute spinal cord injury.
PDF
Jul 20, 2020 Notice
Kringle initiates Phase 3 clinical trial of recombinant human HGF for the treatment of acute spinal cord injury.
PDF
Jun 19, 2020 Notice
Kringle Pharma announces that positive clinical results from Phase I/II trial of recombinant human HGF, KP-100IT, in subjects with acute spinal cord injury were published in the peer-reviewed Journal of Neurotrauma (Published Online: 22 May 2020, DOI: 10.1089/neu.2019.6854).
Apr 07, 2020 Notice
Kringle Pharma additionally raises 740 million Japanese yen toward commercialization of recombinant human HGF drug.
PDF
Mar 02, 2020 Notice
Kringle Pharma successfully raises 950 million Japanese yen to advance clinical development of recombinant human HGF.
PDF
Mar 02, 2020 Notice
Kringle Pharma and Toho Holdings enter into a capital and business alliance for KP-100IT in acute spinal cord injury.
PDF
Dec 26, 2019 AGM
New board members were selected at the 18th general shareholders meeting, and the board members appointed Kiichi Adachi as President and CEO.
Sep 23, 2019 Notice
KP-100IT, recombinant human HGF for the treatment of acute spinal cord injury, was designated as an orphan drug in Japan as of September 12, 2019, with the approval of the Minister of Health, Labor and Welfare.
Jan 07, 2019 Notice
Phase I/II study of recombinant human HGF, KP-100IT, for acute spinal cord injury was completed, and the clinical study report has been issued. The positive results of this study will be published later in a scientific journal and presented at academic conferences.
Jan 07, 2019 Notice
Clinical data from Phase I study of recombinant human HGF, KP-100IT, for the treatment of ALS were published in Journal of Clinical Pharmacology (11 DEC 2018, DOI: 10.1002/jcph.1355). It was indicated that intrathecal administration of KP-100IT was safe and tolerable. Following the Phase I study, an investigator-initiated Phase II study is currently underway to confirm therapeutic efficacy of KP-100IT against ALS.
Dec 21, 2018 AGM
New board members were selected at the 17th general shareholders meeting, and the board members appointed Kiichi Adachi as President and CEO.
Jul 31, 2018 Notice
Kringle Pharma successfully raised 200 million JPY in funding from THVP-1 Fund (General Partner: Tohoku University Venture Partners Co., Ltd.).
Jun 01, 2018 Notice
Kringle’s recombinant human HGF is now available as a research reagent at REPROCELL, Inc. For more information, please contact REPROCELL, Inc. through their website.
May 11, 2018 Notice
Kringle Pharma announces that the last subject has completed the follow-up period after dosing in the Phase I/II study of recombinant human HGF for acute spinal cord injury.
Feb 27, 2018 Notice
A patent entitled ‘HGF preparation suitable for treatment of nervous diseases’ was granted in Japan. Patent No. JP6281992.
Jan 10, 2018 Notice
Clinical data from the investigator-initiated Phase I/II of recombinant human HGF for treatment of vocal fold scar were published in Journal of Tissue Engineering and Regenerative Medicine (25 DEC 2017, DOI: 10.1002/term.2603). It was demonstrated that intracordal injection of the recombinant human HGF drug was safe, feasible, and potentially effective for vocal fold scar patients based on several evaluation methods.
Dec 22, 2017 AGM
New board members were selected at the 16th general shareholders meeting, and the board members appointed Kiichi Adachi as President and CEO.
Dec 22, 2017 Notice
Kringle Pharma announces completion of participant enrollment in the Phase I/II study of recombinant human HGF for acute spinal cord injury.
PDF
Dec 05, 2016 Notice
Kringle Pharma successfully raised 610 milion JPY to accelerate the clinical development of recombinant human HGF.
PDF
Sep 24, 2016 Notice
Kringle Pharma’s project entitled ‘Recombinant human HGF for the treatment of acute spinal cord injury’ was accepted by Japan Agency for Medical Research and Development, AMED, as its Drug Discovery Support Promotion Project.
May 13, 2016 Notice
An investigator-initiated Phase II clinical trial of recombinant human HGF started at the Tohoku and Osaka University Hospitals for the treatment of amyotrophic lateral sclerosis (ALS).
Mar 11, 2015 Notice
Kringle Pharma completed Phase I clinical trial of recombinant human HGF for amyotrophic lateral sclerosis (ALS). Primary objectives of the trial, the safety and pharmacokinetics of the HGF dosing, were successfully evaluated.
Jun 16, 2014 Notice
Kringle Initiates Phase I/II Clinical Trial of Recombinant Human HGF for the Treatment of Acute Spinal Cord Injury.
PDF
Apr 07, 2014 Notice
It is an honor to announce that Professor Kunio Matsumoto at Cancer Research Institute of Kanazawa University, the co-founder and scientific advisor of Kringle Pharma, was awarded the Prizes for Science and Technology, The Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology in Japan. This was awarded to Professor Matsumoto’s prominent achievement of “Development of the application of physiologically active proteins to medical treatment.” Professor Matsumoto has devoted the strenuous efforts for many years to basic research on HGF, hepatocyte growth factor. After founding Kringle Pharma, Professor Matsumoto has been also rendering great help and assistance to the clinical development of recombinant human HGF as a therapeutic agent for intractable diseases. His outstanding contributions and achievements not only in basic science but also in applied research on physiologically active proteins have been highly acclaimed and led him to receive this most treasured prize.
May 17, 2012 Notice
In April 2012, Kringle Pharma completed Phase Ib clinical trial of recombinant human HGF in the United States. Primary objectives of the trial, the safety and pharmacokinetics of multiple intravenous dosing of HGF, were successfully evaluated.
May 01, 2012 Notice
Kringle Pharma’s head office was relocated to the new address.
Oct 24, 2011 Notice
Kringle Pharma’s project entitled ‘Recombinant human HGF for the treatment of spinal cord injury’ is accepted by Japan Science and Technology Agency, JST, as its Adaptable and Seamless Technology transfer Program, A-STEP. This project has been carried out for years having its base on the collaboration with Professors Hideyuki Okano and Yoshiaki Toyama’s group at Keio University School of Medicine. JST will support Kringle to conduct a proof-of -concept clinical study of recombinant Human HGF for the treatment of acute spinal cord injury. The clinical development will be supervised by Assistant professor Masaya Nakamura in Keio University School of Medicine, as a principal investigator.
Jul 08, 2011 Notice
Kringle Initiates Phase I Clinical Trial of Recombinant Human HGF for the Treatment of Incurable Neuronal Diseases.
PDF
Oct 09, 2009 Notice
Kringle Pharma Receives the Grand Prix of the 6th Japan Bio-Venture Award. The Japan Bio-Venture Award was founded in 2001 by Fuji Sankei Business i, one of the general business papers published by Fuji Sankei Communications Group. Since its 1st competition held in 2002, a numbers of Japanese prosperous biotech companies were honored to receive the prizes, which of those are currently playing a major role in the Japanese biotech industry.
Aug 04, 2009 Notice
Kringle Pharma Finishes its Phase Ia Clinical Trial of Recombinant Human HGF for Treatment of Renal Disease.
PDF
Jan 28, 2009 Notice
Kringle Pharma and Maruho Agreed to Conclude an Option Agreement for ChronSeal.
PDF
Jan 28, 2009 Notice
Kringle Pharma Commences a Phase I/II Clinical Trial in Sweden on ChronSeal, a Recombinant Human HGF-Based Therapy for the Treatment of Skin Ulcers.
PDF
Dec 17, 2008 Notice
Kringle Pharma Europe AB Established in Sweden.
PDF
Dec 03, 2008 Notice
Kringle Pharma Initiated a Phase 2 Clinical Trial in Norway on ChronSeal, a Recombinant Human HGF-Based Therapy for the Treatment of Skin Ulcers.
PDF
Oct 30, 2008 Notice
Kringle Pharma Achieved Permission to Conduct Phase 1 Clinical Studies on recombinant human HGF for the Treatment of ARF in US.
PDF
Oct 01, 2008 Notice
Kringle Pharma Files IND Application to FDA to Conduct Studies on recombinant human HGF for the Treatment of ARF.
PDF
Apr 02, 2008 Notice
Kringle Awarded NIBIO R&D Promotion Grant for Clinical Development of Human Recombinant HGF for Neurological Disorders.
PDF
Jan 22, 2008 Notice
Tripep and Kringle Pharma apply cooperatively for permission to launch a Phase II study of ChronSeal.
PDF
Jan 10, 2008 Notice
Kringle Pharma successfully raises additional 157.92 million JPY, following the financing in the previous month.
Dec 25, 2007 AGM
In the 6th annual meeting of shareholders, Keigo Hanada, Director of R&D, appointed and installed as a Member of the Board.
Dec 04, 2007 Notice
Kringle Pharma successfully raises 1.06 billion JPY to accelerate the development of HGF and NK4.
PDF
Nov 20, 2007 Notice
Kringle Pharma forms business alliance with Nippon Zenyaku Kogyo Co., Ltd. to accelerate commercialization of HGF for animal drugs.
PDF
Jul 11, 2007 Notice
Kringle Pharma establishes Joint Research Division for Regenerative Drug Discovery at Osaka University.
PDF
Jun 12, 2007 Notice
Kringle Pharma has completed the manufacture of the required volume of recombinant HGF to conduct initial clinical studies.
PDF
Mar 28, 2007 Notice
Kringle Pharma to initiate a phase I clinical trial of recombinant human HGF for acute renal failure cooperatively with The Rogosin Institute.
PDF
Feb 21, 2007 Notice
Kringle Pharma and Tripep AB, a Swedish biotechnology research company, reached to a basic agreement to co-develop recombinant human HGF (Hepatocyte Growth Factor) protein for wound healing therapy.
PDF
Dec 26, 2006 AGM
As all of the serving board members were approved by shareholders at the 5th annual shareholders meeting (Dec. 22) to be reinstalled to their present positions, Kunio Iwatani was reappointed as President and Chief Executive Officer of Kringle Pharma at the subsequent board of directors meeting, while Kiichi Adachi was reappointed as Executive Vice President.
Nov 06, 2006 Notice
Professor Toshikazu Nakamura of the Graduate School of Medicine at Osaka University and adviser to Kringle Pharma, was awarded the Medal with Purple Ribbon by the Japanese Government on November 3, 2006, for his lifetime scientific contribution to biochemistry.
Apr 07, 2006 Notice
Professor Toshikazu Nakamura (Advisor) and Associate Professor Kunio Matsumoto (Board Member/CSO), Graduate School of Medicine of Osaka University, received Grand Prix of the first Nature Medicine BioMedical Award for the excellent academic research titled “Discovery and therapeutic approach of NK4, an anti-cancer molecule in the 21st century”.
Dec 26, 2005 AGM
A meeting of the board of directors held after the 4th annual meeting of shareholders approved that Kiichi Adachi, Director of the R&D Division, be installed as Executive Vice-President on December 22, 2005, with the aim of strengthening the management. Masayoshi Matsumura resigned as director on December 22, 2005, and was installed as corporate adviser to Kringle Pharma on the same day.
Oct 27, 2005 Notice
Biolex Therapeutics, a US-based company, and Kringle Pharma launched joint research on the development of low-cost mass production methods for NK4, an antitumor protein.
Apr 27, 2005 Notice
Kringle Pharma allocated new shares to third parties to increase its capital by 1,325 million yen.
Apr 06, 2005 Notice
Kringle Pharma concluded a joint research agreement and a license agreement with Nippon Zenyaku Kogyo to place HGF-based drugs for animal use on the market at an early date.
Feb 16, 2005 Notice
Kringle Pharma concluded a joint research agreement on the development of gene medicines with DNAVEC Corporation.
Feb 14, 2005 Notice
Kringle Pharma concluded a research and evaluation agreement with GaleniSearch Laboratories to develop time-release microsphere formulations based on NK4, HGF, and other related compounds.
Dec 17, 2004 AGM
In an annual meeting of shareholders, Kiichi Adachi, Manager of the R&D Division, was appointed and installed as a director.
Oct 01, 2004 Notice
Saito Research Institute was established in the Saito Bio Incubator.
Jul 01, 2004 Notice
The head office was moved to Senri Chuo, Toyonaka City, Osaka.